Related Experiment Video
Updated: Feb 7, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
IDegAsp (insulin degludec + insulin aspart) for the management of type 2 diabetes: current status
Jens Sandahl Christiansen1, Philip Home2, Ajay Kumar3
1a Previously Department of Clinical Medicine - The Department of Endocrinology and Diabetes , Aarhus University , Aarhus , Denmark.
Abstract:
The co-formulation insulin degludec/insulin aspart (IDegAsp) contains insulin degludec (IDeg), a basal insulin, and the rapid-acting insulin aspart (IAsp). Its unique pharmacodynamic profile provides a stable basal insulin action over a 24-h period due to the flat, ultra-long effect of IDeg, combined with prandial control from IAsp, which is unaffected by the basal component. IDegAsp provides a distinct mealtime insulin peak effect and reduces the likelihood of postprandial glucose excursions. The phase 2 and 3 clinical trial program demonstrates that IDegAsp provides effective glycemic control with lower rates of hypoglycemia compared with the current standard of care for insulins. Compared with premixed insulin formulations, IDegAsp allows mealtime flexibility, enabling the time of injection to be adjusted to a different meal(s) on a daily basis to suit changing needs, and has the potential to improve adherence rates. IDegAsp offers a promising new insulin strategy for the treatment of type 2 diabetes.
Related Concept Videos
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Diabetes Mellitus: Type 2 and Gestational
Insulin Secretory Vesicles
Insulin: The Receptor and Signaling Pathways
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

